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Abstract
The purpose is to determine the sufficient extension of margins 
during laser ablation of oral leukoplakia and observe its short-term 
recurrence rate.
Materials and Methods. The study was designed as a randomized 
controlled clinical trial was conducted on 33 oral leukoplakia lesions 
diagnosed in 30 patients (16 Females and 14 Males) with an age range 
between 39 and 79 years. The lesions were divided into three groups; 
Group A: 11 lesions in 11 patients, in which the laser ablation was 
done for the entire lesion without extension of margins; Group B: 
11 lesions in 8 patients, in which the laser ablation was done for the 
lesion adding at least 3mm extension of margins; and finally the Group 
Control: consists of 11 untreated lesions in 11 patients, in which only 
“wait and see” approach was done.
Results. Complete healing of 13 lesions occurred in both groups 
A and B. Complete regression of 3 lesions occurred in Group Control. 
After 6 months of follow-up, 6 of 9 lesions in both groups A and B that 
showed the recurrence, had shown an initial recurrence after 3 weeks 
of the laser ablation. Patients with no history of smoking habits showed 
complete healing of 87.5%, while in ex-smokers complete healing was 
42.8%. The statistical analysis was performed, and the averages of all 
groups are significantly different (p <0.00001).
Discussion. The primary treatment focuses on the elimination of 
associated risk factors (smoking, alcohol, and local irritating factors). 
In the literature, the recurrence rate varies between 13.6% and 40.7%, 
while in our study, it was 45.5% in Group A and 36.4% in Group B.
Conclusion. The recommended extension of margins should be at 
least 3mm in width. Further research can be performed to evaluate the 
immediate re-ablation of the lesions which showed an initial recurrence 
after 3 weeks of laser ablation. Clin Ter 2020; 171 (3):e209-215. doi: 
10.7417/CT.2020.2215
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Introduction
The term Oral Leukoplakia (OL) was defined by the 
World Health Organization (WHO) as “white patch or 
plaque that cannot be characterized clinically or histologi-
cally as any other disease”. This clinical term can be used 
when other white oral lesions have been excluded through 
clinical differential diagnosis and histological examination. 
(1, 2) Recently, the working group on potentially malignant 
disorders, coordinated by the WHO Collaborating Centre 
for Oral Cancer and Precancer, presented new definition of 
leukoplakia “The term leukoplakia should be used to reco-
gnize white plaques of questionable risk having excluded 
other known diseases or disorders that carry no increased risk 
for cancer”. This is a novel relevant element that emphasizes 
the real risk of malignant change during follow-up of certain 
alterations identified at the first assessment as ‘’leukoplakia’’ 
in some areas of the oral tissue. (3) Its appearance in oral 
cavity usually takes place after the age of 30 years, resulting 
in a peak of incidence above the age of 50. (4, 5)
The elimination of suspected etiological factors should 
be accomplished. In case of persistent lesions (no signs of 
regression within 2 weeks), an identification by histopatho-
logical examination should be performed to have a definitive 
clinical diagnosis of OL. 
The prevalence of OL in the population is 1-5%, vary 
among the oral anatomical sites and demographic groups. 
(6) The OL annual malignant transformation rate is 1%, 
however many authors suggest that this percentage would 
be higher following the proper diagnosis of OL. In a study 
by Woo et al, (7) 57.1% of cases of True Leukoplakia (TL) 
were diagnosed as “Keratosis of Unknown Significance” 
(KUS) when all frictional keratosis were excluded.
OL is one of the Oral Potentially Malignant Disorders 
(OPMDs), thus its diagnosis is essential because of the pre-
malignant potential and its need to be managed differently 
from other white lesions (8).
The management of OL includes various treatment 
modalities with a low success rate in a long follow-up such 
as: surgical treatment, medical therapy, and nonsurgical 
treatments such as vitamin A, retinoid, beta carotene or 
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carotenoids, non-steroidal anti-inflammatory drugs, herbal 
extracts, bleomycin, and Bowman–Birk inhibitor. (9)
The conventional types of surgical treatments are done 
by scalpel excision, electrosurgery, and cryosurgery. The 
recurrence rate varies from 10% to 34% for scalpel excision 
and from 12% to 25% for cryosurgery. These modalities 
cause tissue scarring and contraction, which can mask early 
signs of recurrence. (10)
The use of laser for surgical treatment of OL is reported. 
Different laser wavelengths are proposed: CO
2
, Nd:YAG, 
Er:YAG, and diode laser. The CO
2
 laser in comparison with 
the other laser wavelengths can superficially remove the soft 
tissues by ablation with minimal thermal damage to adjacent 
tissue and good haemorrhage control (11, 12), which results 
in a minimal tendency to scar and little postoperative pain 
and edema. (13, 14)
The surgical procedures and their success rates are 
different and multiple. However, a gold standard surgical 
protocol for the treatment of OL by laser beam is still needed 
to improve the success rate. (13) It was preferred to use the 
expression “laser ablation” to indicate the complete removal 
of the lesion by laser.
The aim of this study is to determine the adequate Ex-
tension of Margins (EM) during CO
2
 laser ablation of OL 
and observe its short-term recurrence rate.
Materials and Methods
The study was designed as a randomized controlled 
clinical trial (CE Prot. n.729). Patients were recruited in 
the Department of Oral Sciences and Maxillofacial Sur-
gery, Sapienza University of Rome. All the interventions 
were performed by the same oral surgeon and conducted 
according and passing the online examination for the Certi-
ficate in Essential Good Clinical Practice (GCP) (Certificate 
number: EGCP19/3015) and following the guidelines of the 
World Medical Association Declaration of Helsinki (15). 
All participants underwent the same procedures without 
any deviation from protocol during the entire trial and were 
informed about the methods of treatment (with or without 
EM) and the randomization procedure and gave written 
informed consent.
Full clinical examination consisted of medical and dental 
history were performed. Patients were photographed with the 
same equipment (Nikon D200, Nikon Corporation, Tokyo, 
Japan). Elimination of associated risk factors was done for 
all the patients. An oral swab was done for all the lesions to 
exclude any fungal infection, moreover conventional blade 
biopsy was performed on all the lesions. Multiple biopsies 
were performed for large lesions more than 20mm. All sur-
gical specimens were preserved in neutral-buffered formalin 
solution (10%) and sent for histopathological evaluation to 
confirm the diagnosis of TL by a pathologist. The histopa-
thological evaluation confirmed that all the lesions were 
“hyperkeratosis with no evidence of dysplasia”.
One month after the histological diagnosis, patients were 
treated following the protocol for the complete ablation with 
the CO
2
 laser. Local anesthesia was performed by 1.8 ml of 
Mepivacaine solution with adrenaline (Mepivacaina Pierrel, 
30 mg/ml, injection solution 1.8 ml, Pierrel S.p.A., Milan, 
Italy) and was applied around the OL lesion.
The inclusion criteria for the lesions to be enrolled in 
the study were: the presence of white lesion in the oral ca-
vity for two weeks after the elimination of associated risk 
factors, oral swab to exclude any fungal infection, conven-
tional blade biopsy to confirm histopathologically that the 
lesion is “hyperkeratosis with no evidence of dysplasia” to 
confirm the clinical diagnosis of “Keratosis of Unknown 
Significance” (KUS)
The exclusion criteria: hyperkeratosis with evidence of 
dysplasia and any other white lesions.
Patient’s enrollment was performed following the CON-
SORT (Consolidated Standards of Reporting Trials) criteria 
(Table 1); 43 OL lesions in 17 males and 19 females. Ten 
lesions were excluded (not matching the inclusion criteria 
(n = 5), declined to participate (n = 4), or for other reasons 
(n = 1)).
This study was performed on 33 lesions, in 30 patients. 
The patients age range was between 39 and 79 years old, of 
which 14 were males (47%) and 16 females (53%). Patients 
were randomly distributed into three groups according to a 
computer-generated series. The web Research Randomizer® 
free resource for researcher was used for randomization:
- Group A (GA): 11 OL lesions in 11 patients. The laser 
ablation was done for the entire lesion without EM.
- Group B (GB): 11 OL lesions in 8 patients. The laser 
ablation was done for the lesion adding at least 3mm of 
EM.
- Group Control (GC): 11 OL lesions in 11 patients. No 
treatment was prescribed. Only a periodic six months 
follow-up “wait and see” approach was done.
Large lesions (more than 20mm) were divided into sec-
tions that were ablated with a distance of at least 2 months 
(compartmentalization of the lesion). All the lesions and 
extended borders were ascertained using a sterile dermogra-
phic pen. The EM was measured using a periodontal probe 
(Sklar’s®, Goldman-Fox Probe, West Chester, PA, USA)
The laser device employed was CO
2
 Laser (SMART US-
20D®, DEKA, Florence, Italy, 10600 nm) using a power of 
4.5 Watts on PW, 80 Hz, fluence of 44.78 J/cm2, and a spot 
diameter of 400 μm. 
The laser was used in defocused mode (1-2 mm distance 
to the mucosa). The wound surface was ablated in scanning 
movements, vertical and horizontal, to remove at least 3mm 
in depth except in gingival lesions the maximum depth was 
1mm for the elimination of any remnants of the lesion.
All laser ablated wounds were left to open granulation 
and secondary epithelialization. The prescribed medication 
for the patients in GA and GB was 0.2% Chlorhexidine 
spray (Corsodyl®, GlaxoSmithKline Consumer Healthcare 
S.p.A, Baranzate, Milan, Italy) prescribed for three times a 
day for one week. 
Four follow-up visits were performed according to this 
schedule: one week, 3 weeks, 3 months, and 6 months.
Recurrence rate evaluation in GA and GB was divided 
into two categories: complete healing and recurrence, while 
in GC was divided into two categories: complete regression 
and no change. The collected data of the study was analy-
sed and the statistical analysis was performed (Student-
Newman–Keuls multiple comparison).
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Results
The one-way analysis of variance statistical analysis 
coupled to the Student-Newman–Keuls multiple comparison 
between the success rate (Complete healing and complete 
regression) post-hoc test showed that the averages of all 
groups are significantly different (p < 0.00001; F: 3.292). 
Thus, the averages of success rates in all the groups are 
significantly different (Table 2).
The results of different groups (n=33) pointed out a 
percentage of regression of 27.3% for the GC (only follow-
up), percentage of healing of 54.5% for the GA (ablation 
without EM) and 63.6% for the GB (ablation with EM of 
3mm) (Table 3).
No differences were clinically detected in the healing 
process. In general, good healing process and minimal 
post-operative pain or discomfort were shown by all the 
patients. 
Groups N     Subset for alpha = 0.05
1 2 3
Group Control 11 27.27 %
Group A 11 54.54 %
Group B 11 63.63 %
Sig. 1.000 1.000 1.000
Table 2. The one-way analysis of variance statistical analysis coupled to the Student-Newman–Keuls multiple comparison.
Table 1. CONSORT (Consolidated Standards of Reporting Trials) of the study
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After 6 months of follow-up, 6 of 9 lesions in both GA 
and GB that showed the recurrence, had shown an initial 
recurrence after 3 weeks of the laser ablation (Fig. 1).
The complete healing occurred in 13 lesions (59%) 
among the GA and GB. While the complete regression was 
observed in 3 lesions (27.3%) in the GC.
In GA, the complete healing occurred in 6 lesions 
(54.5%) and the recurrence occurred in 5 lesions (45.5%) 
(Fig. 2). While in GB, the complete healing occurred in 7 
lesions (63.6%) (Fig. 3) and the recurrence occurred in 4 
lesions (36.4%).
Table 3 The different rates of healing are shown for each group. 
Table 3. The different rates of healing are shown for each group
 
Figure 1 (A) Oral leukoplakia lesion on the tongue; (B) Immediately after CO2 laser ablation with EM; (C) Follow-up after 3 weeks 
shows initial recurrence. 
Fig. 1. (A). Oral leukoplakia lesion on the tongue; (B) Immediately after CO2 laser ablation with EM; (C) Follow-up after 3 weeks shows 
initial recurrence.
 
Figure 2 (A) Oral leukoplakia on the gingiva; (B) Immediately after CO2 laser ablation without EM; (C) Follow up after 6 months 
shows the recurrence. 
Fig. 2. (A) Oral leukoplakia on the gingiva; (B) Immediately after CO2 laser ablation without EM; (C) Follow up after 6 months shows the 
recurrence.
 
Figure 3 (A) Oral leukoplakia lesion on the buccal mucosa; (B) Immediately after laser ablation with EM; (C) Follow-up after 6 
months shows complete healing. 
Fig. 3. (A) Oral leukoplakia lesion on the buccal mucosa; (B) Immediately after CO2 laser ablation with EM; (C) Follow-up after 6 months 
shows complete healing.
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The complete healing was observed in 75% of females 
and 44% of males. Furthermore, the smoking habits had 
a significant relation with the complete healing as it was 
found that the percentage of complete healing in ex-smoking 
patients was 42.8% (6 of 14 lesions).
The highest percentage of complete healing according to 
the anatomical site was observed in lesions of the palate and 
floor of the mouth (Table 4). During the follow-up period, 
none of the patients showed an oncological oral transforma-
tion, and no reported complications were observed. 
Discussion
OL monitoring showed that the lesion may regress un-
predictably, remain stable, or may progress to oral squamous 
cell carcinoma (16). The primary treatment of OL focuses on 
the suppression of associated etiological factors (smoking, 
local irritating factors, etc.) (17).
The main advantages of laser therapy are the potential 
haemostatic effects especially for patients with contraindi-
cations to the traditional surgery, the potential for limited 
tissue contraction and post-therapy scarring. Which may 
permit the treatment of lesions with large dimensions.
It is extremely important to accurately diagnose and 
differentiate between reactive or inflammatory keratotic 
conditions and OL. Because of its pre-cancerous nature, 
the management of OL should be performed through a clo-
se follow-up or complete removal. Not all white keratotic 
lesions on the oral mucosa are OL, as noted in the WHO 
definition. The oral mucosa becomes white for the following 
reasons: Excess production of keratin as a response to injury 
(e.g. friction or biting), excess production of keratin intrinsi-
cally from benign keratotic diseases (e.g. genodermatoses) 
or dysplasia, thickening of the epithelium (acanthosis), and/
or damage of epithelial cells from direct and/or identifiable 
contact injury (6, 18).
In case of persistence of the hyperkeratosis, an oral 
biopsy is necessary. OL is potentially malignant lesion, 
therefore, OL should be treated (9, 19). 
Non-homogeneous OL carries a higher risk of mali-
gnant transformation, when compared to the homogeneous 
variance. (20) Regarding non-surgical treatments (retinoid, 
bleomycin, local use of corticosteroid, etc.), the available 
evidence on medical and complementary interventions for 
treating OL is very limited. The relapses and adverse effects 
are common; the recurrence of OL after surgical treatment 
has been reported between 13.6 and 40.7% (21).
Further, Kuribayashi et al. (22) showed a long-term 
outcome (10 years) of non-surgical treatment of OL. Their 
results indicated that on 237 observed lesions, 135 lesions 
(57%) were remained unchanged, 30 (12.7%) lesions were 
characterized by a reduction in size, and 44 (18.6%) lesions 
were disappeared. While another 11 (4.6%) lesions developed 
oral squamous cell carcinoma. In their conclusion, the authors 
indicated that the development of appropriate treatments for 
OL is required, which will enable successful differentiation 
between surgical and observational treatment plans. Those 
results show the necessity to develop a more efficient pro-
phylactic and acceptable permanent therapy for OL.
According to Van der Waal (18), four steps of certainty 
C factor (C1, C2, C3, C4) may be useful in the diagnosis of 
OL including C1 (provisional clinical diagnosis), C2 (defi-
nitive clinical diagnosis), C3 (definitive clinicopathological 
diagnosis in case of incisional biopsy) and C4 (definitive 
clinicopathological diagnosis in case of excisional biopsy 
or surgical excision after an incisional biopsy). So that the 
diagnosis of OL may be provisional or definitive and asso-
ciated with a variable degree of certainty factor.
Our study was conducted on 33 lesions diagnosed with 
OL. A certainty factor of C3 was assigned to all the lesions, 
based on the evidence obtained by non-regression of the pa-
thological framework after the elimination of the associated 
risk factors for a period of two weeks.
Group Control Group A Group B
Number of lesions 11 11 11
Gender
  Male
  Female
4 (36.4 %)
7 (63.6 %)
6 (54.5 %)
5 (45.5 %)
4 (50 %)
4 (50 %)
Smoking habits
  Non smoking
  Ex-smoker
8 (72.7 %)
3 (27.3 %
4 (36.4 %)
7 (63.6 %)
4 (36.4 %)
7 (63.6 %)
Anatomical Site
  Tongue
  Palate
  Buccal mucosa
  Attached gingiva
  Floor of the mouth
1 (9.1 %)
4 (36.3 %)
3 (27.3 %)
3 (27.3 %)
1 (9.1 %)
3 (27.3 %)
1 (9.1 %)
4 (36.3 %)
2 (18.2 %)
5 (45.4 %)
2 (18.2 %)
3 (27.3 %)
1 (9.1 %)
Laser technique No laser Ablation without EM Ablation with EM
Healing / Regression Rate 3 (27.3 %) Complete regression
8 (72.7 %) No change
6 (54.5 %) Complete healing
5 (45.5 %) Recurrence
7 (63.6 %) Complete healing
4 (36.4 %) Recurrence
Follow-up 6 months 6 months 6 months
Table 4. An overview of the study.
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In addition to incisional biopsy for small lesions and mul-
tiple incisional biopsies for large lesions, a histopathological 
report confirmed that no other clearly defined lesions were 
revealed. Although histopathological diagnosis was obtained 
through an incisional biopsy, there are studies in the literature 
that show the possible differences between the results of an 
incisional biopsy and those related to an excisional biopsy 
causing, in some cases, the failure to diagnose dysplastic 
or neoplastic lesions.
The anatomical distributions of the lesions in this study 
showed a predominant appearance on the gingival mucosa 
30.3% (10 of 33 lesions). On the other hand, in a study 
conducted by Brouns et al. (23) and in another conducted by 
Mogedas-Vegara et al. (24), the most common anatomical 
site was the lateral border of the tongue. 
Laser ablation is one of the treatment modalities avai-
lable for the management of OL which guarantees a less 
complicated postoperative pain, edema, minor inflammatory 
complications, preservation of the mobility and functionality 
of the treated tissue (25, 26, 27, 28), and based on our results, 
it shows a lower recurrence rate.
In our study, there were some limitations that should be 
considered. Including OL lesions with the same site and size 
for each group was one of the major limitations of the study. 
Another limit  may be related to the presence of some normal 
variables such as gender and age, that might increase the 
difficulty to standardize the results for the population treated 
in normal life. In fact, the major limitation of any rando-
mized clinical trials is their restriction to interventions that 
are supposed to have a positive effect. In addition, clinical 
trials can not usually provide complete solid answers to the 
questions asked by practitioners and deciders. (29)
Although there is still no unanimity about the most su-
itable treatment for OL, the collected data from our study 
demonstrated that complete healing occurred in 13 lesions 
(59%) among both GA, GB and complete regression of 3 
lesions (27.3%) in the GC after six months of follow-up.
Pedrosa et al. (30) conducted a study on patients with OL, 
treated with CO
2
 laser with a lateral extension of 2mm to the 
apparent clinical margins of the lesion reaching a depth of 
about 5mm; while on the gingival and hard palate lesions, 
the surgical depth was about 2mm and the recurrence rate 
was 40.7% (24 of 59 lesions).
The selection of the 3mm of EM for GB was done based 
on a retrospective study conducted by Kuribayashi et al. (31), 
in which 53 lesions of OL were present in 52 patients treated 
by surgical excision. It was found that the free recurrence 
rate in patients with resection margins >3mm in width was 
significantly higher than that in patients with resection mar-
gins <3mm; thus, advising that the optimal safety margins 
should be at least 3mm in width and a deep surgical margin 
may relate to the recurrence of OL.
OL may be a complex lesion. It is derived from one or 
several clones of cells within an extended oral mucosal area 
comprising other clones of cells characterized by clinically 
invisible changes “Field of Cancerization”. The new epi-
thelium of potentially unstable mucosa that migrates from 
the periphery to cover the wound might be the cause of 
the recurrence. This may explain the development of new 
patches of OL, adjacent to the margins of previously treated 
areas. (32)
The results of this study highlight a better outcome 
achieved by adding 3mm of EM beyond the clinical limit 
of the lesion since the complete healing at 6 months was 
higher for GB than GA.
The anatomical site in which the highest prevalence of 
OL in our study was the attached gingiva; the mean mar-
ginal thickness for gingival tissue is usually only 1.25mm. 
So that it is too thin to resect with sufficient safety margins. 
As a result, the lesions on the gingival mucosa were of a 
significant risk factor for recurrence.
Conclusion
It is preferred to treat OL not to leave it for “wait and 
see” or “watch-and-see” approaches. It is important to 
ascertain the borders of the lesions to detect if the peripheral 
recurrence occurred.
The recommended EM should be at least 3mm in width. 
Also, deep surgical margins may be related to the recurrence 
of OL. Dividing large lesions, more than 20mm, into multi-
ple sections for laser ablation could be a solution to reduce 
the post-operative symptoms and malfunctions.
Further research can be performed to evaluate the im-
mediate re-ablation of the lesions which showed an initial 
recurrence after 3 weeks of ablation.
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